The first clinical trial of copper-ATSM as a potential treatment option for MND will start in 2016. Importantly, copper-ATSM therapy was developed in Australia, the first-in-man clinical study is being performed in Australia, and the sponsor is an Australian company (CMD). 

Read an overview of the copper-ATSM research that has been performed to date, the rationale for why this compound may be an effective treatment, and the status of the clinical trial.


Subscribe to news and updates